<b>Increased early postprandial glucagon concentrations in humans with newly diagnosed type 2 diabetes and steatotic liver disease</b>
Maximilian Huttasch(Deutsches Diabetes-Zentrum e.V.), GDS Group, Yuliya Kupriyanova(Deutsches Diabetes-Zentrum e.V.), Philipp Westhoff, Nicolai J Wewer Albrechtsen, Vera Schrauwen-Hinderling, Robert Wagner, Michael Roden, Sabine Kahl, Martin Schön, Patrick Schrauwen, Tim Mori, Sandra Trenkamp, Geronimo Heilmann(University of Duisburg-Essen)
Cited by 0
Related Papers
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
|Metabolism|2024|137
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
|Proceedings of the National Academy of Sciences|2025|33
Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
|Diabetes|2023|11
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes
|Liver International|2023|8
Zelkovamycin is an OXPHOS Inhibitory Member of the Argyrin Natural Product Family
|Chemistry - A European Journal|2020|7